vs
Side-by-side financial comparison of MANHATTAN BRIDGE CAPITAL, INC (LOAN) and MILESTONE SCIENTIFIC INC. (MLSS). Click either name above to swap in a different company.
MANHATTAN BRIDGE CAPITAL, INC is the larger business by last-quarter revenue ($2.1M vs $2.1M, roughly 1.0× MILESTONE SCIENTIFIC INC.). MANHATTAN BRIDGE CAPITAL, INC runs the higher net margin — 61.6% vs -53.0%, a 114.6% gap on every dollar of revenue. On growth, MILESTONE SCIENTIFIC INC. posted the faster year-over-year revenue change (2.2% vs -9.1%). Over the past eight quarters, MILESTONE SCIENTIFIC INC.'s revenue compounded faster (-4.3% CAGR vs -8.0%).
Manhattan Bridge Capital, Inc. is a U.S.-based real estate finance firm that provides short-term asset-backed secured loans primarily to real estate investors. Its core offerings include bridge loans for residential and commercial property acquisitions, rehabilitation, and refinancing, serving clients across key U.S. real estate markets.
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
LOAN vs MLSS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1M | $2.1M |
| Net Profit | $1.3M | $-1.1M |
| Gross Margin | — | 73.0% |
| Operating Margin | 61.4% | -52.5% |
| Net Margin | 61.6% | -53.0% |
| Revenue YoY | -9.1% | 2.2% |
| Net Profit YoY | -7.2% | 46.4% |
| EPS (diluted) | $0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.1M | — | ||
| Q4 25 | $2.0M | $2.1M | ||
| Q3 25 | $2.0M | $2.4M | ||
| Q2 25 | $2.4M | $2.3M | ||
| Q1 25 | $2.3M | $2.2M | ||
| Q4 24 | $2.4M | $2.0M | ||
| Q3 24 | $2.3M | $2.5M | ||
| Q2 24 | $2.4M | $1.9M |
| Q1 26 | $1.3M | — | ||
| Q4 25 | $1.1M | $-1.1M | ||
| Q3 25 | $1.2M | $-1.2M | ||
| Q2 25 | $1.4M | $-1.5M | ||
| Q1 25 | $1.4M | $-2.0M | ||
| Q4 24 | $1.3M | $-2.0M | ||
| Q3 24 | $1.4M | $-1.5M | ||
| Q2 24 | $1.4M | $223.6K |
| Q1 26 | — | — | ||
| Q4 25 | — | 73.0% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | — | 69.6% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | 75.0% | ||
| Q3 24 | — | 73.0% | ||
| Q2 24 | — | 76.1% |
| Q1 26 | 61.4% | — | ||
| Q4 25 | 55.9% | -52.5% | ||
| Q3 25 | 58.8% | -48.1% | ||
| Q2 25 | 59.9% | -63.9% | ||
| Q1 25 | 60.2% | -89.5% | ||
| Q4 24 | 55.2% | -101.4% | ||
| Q3 24 | 60.3% | -58.4% | ||
| Q2 24 | 57.5% | -96.0% |
| Q1 26 | 61.6% | — | ||
| Q4 25 | 56.1% | -53.0% | ||
| Q3 25 | 59.1% | -48.9% | ||
| Q2 25 | 60.0% | -63.8% | ||
| Q1 25 | 60.4% | -89.3% | ||
| Q4 24 | 55.4% | -101.1% | ||
| Q3 24 | 60.5% | -58.1% | ||
| Q2 24 | 57.7% | 12.1% |
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.11 | $-0.01 | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.12 | — | ||
| Q4 24 | $0.12 | — | ||
| Q3 24 | $0.12 | $-0.02 | ||
| Q2 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $43.1M | $2.8M |
| Total Assets | $64.3M | $7.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | — | $5.8M |
| Q1 26 | $43.1M | — | ||
| Q4 25 | $43.1M | $2.8M | ||
| Q3 25 | $43.3M | $2.5M | ||
| Q2 25 | $43.4M | $3.3M | ||
| Q1 25 | $43.3M | $4.5M | ||
| Q4 24 | $43.3M | $5.8M | ||
| Q3 24 | $43.3M | $7.2M | ||
| Q2 24 | $43.2M | $8.0M |
| Q1 26 | $64.3M | — | ||
| Q4 25 | $62.4M | $7.8M | ||
| Q3 25 | $60.0M | $8.5M | ||
| Q2 25 | $67.6M | $8.1M | ||
| Q1 25 | $65.8M | $9.1M | ||
| Q4 24 | $67.4M | $9.8M | ||
| Q3 24 | $70.7M | $11.2M | ||
| Q2 24 | $68.8M | $12.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $-226.1K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.3M | — | ||
| Q4 25 | $4.9M | $-226.1K | ||
| Q3 25 | $1.4M | $81.8K | ||
| Q2 25 | $1.2M | $-1.8M | ||
| Q1 25 | $1.2M | $-1.0M | ||
| Q4 24 | $4.9M | $-1.5M | ||
| Q3 24 | $1.2M | $-973.9K | ||
| Q2 24 | $1.3M | $783.7K |
| Q1 26 | — | — | ||
| Q4 25 | $4.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 246.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 208.9% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | — | — |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 4.39× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 0.87× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 3.78× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.91× | 3.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
